Grant: Doctoral Research Award - PA: Hypertension (SHOPP)
University of Alberta
$52,500.00
An evaluation of the management of hypertension by pharmacists with prescribing authorization, and the clinical effectiveness and feasibility of remunerating pharmacists for providing clinical hypertension care to improve cardiovascular outcomes
EF 2011-12
Résumé
High blood pressure (BP) can contribute to heart attack, stroke, and heart failure, and is often easily controlled with lifestyle and drug therapy, making pharmacists capable of caring for patients with high BP due to their drug therapy expertise. Previous research has shown that community pharmacy BP programs can lower BP more effectively than usual physician-based care, even when the pharmacist is limited to making drug therapy recommendations to the patient's physician who must prescribe drug changes.
The province of Alberta allows pharmacists to prescribe medications. Here, we are conducting a study where patients are randomized to pharmacist-based care (monthly pharmacist BP assessment with medication adjustment) or usual care for 6 months. Since the sustainability of this type of program requires pharmacists to be paid for their time, we are also studying two different pay methods: (1) fee-for-service (a flat fee paid per visit regardless of BP outcomes) and (2) payment-for-performance (a flat fee per visit with bonuses for lowering BP to certain levels). We will be studying whether pharmacists with prescribing authorization are able to lower patients' BP moreso than usual care, and also studying whether BP lowering achieved depends on how pharmacists are paid.
We will also review the literature to determine if payment-for-performance for health professionals has an impact on the quality or cost-effectiveness of care provided to patients, and also to see how pharmacists are paid worldwide for providing care through similar programs and the outcomes achieved by those programs.
Our goal is to study the effectiveness of pharmacist care including prescribing in lowering BP, and how we should be paying pharmacists for their time. Pharmacist management of high BP can potentially lower a patient's risk of heart attack, stroke, or heart failure, and also potentially improve patients' access to care reducing the burden of chronic disease in the population.
Programme
Doctoral Research Award - PA: Hypertension (SHOPP)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
245829
Name
Houle Sherilyn
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Hypertension Canada (Markham, Ontario)
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
An evaluation of the management of hypertension by pharmacists with prescribing authorization, and the clinical effectiveness and feasibility of remunerating pharmacists for providing clinical hypertension care to improve cardiovascular outcomes
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$52,500
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Hypertension (SHOPP)
Keyworddelim
Chronic Disease Management; Health Professional Remuneration; Hypertension; Interprofessional Collaboration; Patient-Centered Care; Pharmacist Prescribing; Pharmacy Practice; Practice-Based Research; Randomized Controlled Trial; Systematic Review
Abstract
High blood pressure (BP) can contribute to heart attack, stroke, and heart failure, and is often easily controlled with lifestyle and drug therapy, making pharmacists capable of caring for patients with high BP due to their drug therapy expertise. Previous research has shown that community pharmacy BP programs can lower BP more effectively than usual physician-based care, even when the pharmacist is limited to making drug therapy recommendations to the patient's physician who must prescribe drug changes.
The province of Alberta allows pharmacists to prescribe medications. Here, we are conducting a study where patients are randomized to pharmacist-based care (monthly pharmacist BP assessment with medication adjustment) or usual care for 6 months. Since the sustainability of this type of program requires pharmacists to be paid for their time, we are also studying two different pay methods: (1) fee-for-service (a flat fee paid per visit regardless of BP outcomes) and (2) payment-for-performance (a flat fee per visit with bonuses for lowering BP to certain levels). We will be studying whether pharmacists with prescribing authorization are able to lower patients' BP moreso than usual care, and also studying whether BP lowering achieved depends on how pharmacists are paid.
We will also review the literature to determine if payment-for-performance for health professionals has an impact on the quality or cost-effectiveness of care provided to patients, and also to see how pharmacists are paid worldwide for providing care through similar programs and the outcomes achieved by those programs.
Our goal is to study the effectiveness of pharmacist care including prescribing in lowering BP, and how we should be paying pharmacists for their time. Pharmacist management of high BP can potentially lower a patient's risk of heart attack, stroke, or heart failure, and also potentially improve patients' access to care reducing the burden of chronic disease in the population.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Houle, Sherilyn
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $52,500~ $0~